Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. McShane · SciRah

Researcher profile · Semantic Scholar

L. McShane

Share profile

L. McShane — researcher profile on SciRah

h-index: 87
Works: 313
Citations: 51K

Most-cited papers

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
K. Allison, M. Hammond, M. Dowsett, Shannon E McKernin +16 more
2020Journal of Clinical Oncology1,298 citations Open access
Semantic Scholar
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
T. Nielsen, S. Leung, D. Rimm, A. Dodson +18 more
2020Journal of the National Cancer Institute724 citations Open access
Semantic Scholar
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
Antonio C. Wolff, M. Somerfield, M. Dowsett, M. Hammond +5 more
2023Journal of Clinical Oncology582 citations
Semantic Scholar
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Diana M. Merino, L. McShane, D. Fabrizio, V. Funari +29 more
2020Journal for ImmunoTherapy of Cancer448 citations Open access
Semantic Scholar
TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository
Ying-Dong Zhao, Ming-Chung Li, Mariam M. Konaté, Li Chen +6 more
2021Journal of Translational Medicine399 citations Open access
Semantic Scholar
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
K. Allison, M. Hammond, M. Dowsett, Shannon E McKernin +16 more
2020Archives of Pathology & Laboratory Medicine303 citations Open access
Semantic Scholar
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
A. K. Salama, Shu-Li Li, Erin R. Macrae, Jong-In Park +16 more
2020Journal of Clinical Oncology252 citations Open access
Semantic Scholar
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
K. Flaherty, R. Gray, Alice P. Chen, Shu-Li Li +21 more
2020Journal of Clinical Oncology233 citations Open access
Semantic Scholar
Criteria for the translation of radiomics into clinically useful tests
Erich P Huang, J. O'Connor, L. McShane, M. Giger +4 more
2022Nature Reviews Clinical Oncology232 citations Open access
Semantic Scholar
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
K. Flaherty, R. Gray, Alice P. Chen, Shu-Li Li +35 more
2020Journal of the National Cancer Institute183 citations Open access
Semantic Scholar
The NCI-MATCH trial: Lessons for precision oncology
P. O'Dwyer, R. Gray, K. Flaherty, Alice P. Chen +22 more
2023Nature Medicine163 citations Open access
Semantic Scholar
Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.
D. M. Vega, Laura M. Yee, L. McShane, P. Williams +46 more
2021Annals of Oncology161 citations Open access
Semantic Scholar
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
N. L. Henry, M. Somerfield, Z. Dayao, A. Elias +11 more
2022Journal of Clinical Oncology119 citations Open access
Semantic Scholar
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update.
A. Wolff, M. Somerfield, M. Dowsett, M. Hammond +5 more
2023Archives of Pathology & Laboratory Medicine109 citations Open access
Semantic Scholar
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Y. Chae, F. Hong, C. Vaklavas, Heather H. Cheng +18 more
2020Journal of Clinical Oncology109 citations Open access
Semantic Scholar
Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges
J. Rahnenführer, R. de Bin, A. Benner, F. Ambrogi +7 more
2023BMC Medicine101 citations Open access
Semantic Scholar
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group
James H. Godsey, A. Silvestro, J. C. Barrett, K. Bramlett +16 more
2020Clinical Chemistry92 citations Open access
Semantic Scholar
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
D. Wheeler, N. Takebe, T. Hinoue, K. Hoadley +42 more
2020Cancer Cell88 citations Open access
Semantic Scholar
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
K. Kalinsky, F. Hong, Carolyn K. McCourt, J. Sachdev +16 more
2020JAMA Oncology84 citations Open access
Semantic Scholar
Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131)
Douglas B. Johnson, Feng-Min Zhao, M. Noel, Gregory Riely +16 more
2020Clinical Cancer Research64 citations Open access
Semantic Scholar
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S. Damodaran, Feng-Min Zhao, D. Deming, E. Mitchell +15 more
2022Journal of Clinical Oncology62 citations Open access
Semantic Scholar
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
F. Meric-Bernstam, J. Ford, P. O'Dwyer, G. Shapiro +19 more
2023Clinical Cancer Research48 citations Open access
Semantic Scholar
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
J. Cleary, V. Wang, R. Heist, E. Kopetz +20 more
2021Clinical Cancer Research34 citations Open access
Semantic Scholar
The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study.
B. Conley, L. Staudt, N. Takebe, D. Wheeler +35 more
2020Journal of the National Cancer Institute30 citations Open access
Semantic Scholar
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
I. Krop, Opeyemi A. Jegede, J. Grilley-Olson, J. Lauring +21 more
2022JCO Precision Oncology24 citations Open access
Semantic Scholar
REMARK guidelines for tumour biomarker study reporting: a remarkable history
D. F. Hayes, W. Sauerbrei, L. McShane
2022British Journal of Cancer22 citations
Semantic Scholar
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B. Wisinski, Yael Flamand, M. Wilson, J. Luke +20 more
2023JCO Precision Oncology21 citations Open access
Semantic Scholar
Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products
J. Krushkal, Simarjeet Negi, Laura M. Yee, Jason R. Evans +7 more
2020Molecular Oncology21 citations Open access
Semantic Scholar
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
F. Meric-Bernstam, Michael W Lloyd, Soner Koc, Yvonne A. Evrard +30 more
2024Molecular Cancer Therapeutics18 citations Open access
Semantic Scholar
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
P. Bedard, Shu-Li Li, Kari B. Wisinski, E. Yang +17 more
2022JCO Precision Oncology17 citations Open access
Semantic Scholar
Phase 2 Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K1
Jun Gong, Alain C. Mita, Zi-Han Wei, Heather H. Cheng +18 more
2024JCO Precision Oncology16 citations Open access
Semantic Scholar
The New NCI Precision Medicine Trials
L. Harris, C. Blanke, H. Erba, J. Ford +21 more
2023Clinical Cancer Research16 citations Open access
Semantic Scholar
Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP‐sponsored clinical trials before and after launch of the NCI National Clinical Trials Network
H. Sankaran, S. Finnigan, L. McShane, Ana F. Best +1 more
2022Cancer16 citations Open access
Semantic Scholar
Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts
Mariam M. Konaté, Julia Krushkal, Ming-Chung Li, Li Chen +7 more
2024Journal of Translational Medicine15 citations Open access
Semantic Scholar
Perspectives on statistical strategies for the regulatory biomarker qualification process
S. Hendrix, R. Mogg, Sue-Jane Wang, Aloka G Chakravarty +4 more
2021Biomarkers in Medicine15 citations Open access
Semantic Scholar
Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project
H. Andrews, L. McShane, Elise C. Kohn, R. Arend +33 more
2024JCO Oncology Advances13 citations Open access
Semantic Scholar
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
A. Clark, F. Hong, R. Finn, A. DeMichele +19 more
2023Clinical Cancer Research11 citations Open access
Semantic Scholar
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
D. F. Hayes, R. Herbst, J. Myles, S. Topalian +22 more
2022JCO Precision Oncology11 citations Open access
Semantic Scholar
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images.
B. McKelvey, Pedro A. Torres-Saavedra, Jessica Li, G. Broeckx +37 more
2026Modern Pathology10 citations Open access
Semantic Scholar
Phase 2 Study of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2
Jun Gong, Alain C. Mita, Zi-Han Wei, Heather H. Cheng +17 more
2024JCO Precision Oncology10 citations
Semantic Scholar
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration.
Donna R Rivera, Tracy L. Cutler, L. McShane, Ann Meeker-O’Connell +39 more
2025JAMA Network Open9 citations Open access
Semantic Scholar
Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective
D. Hertz, L. McShane, D. F. Hayes
2022Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek
L. McShane, Mark Rothmann, T. Fleming
2023Clinical Trials8 citations Open access
Semantic Scholar
Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials
Laura M. Yee, L. McShane, B. Freidlin, M. Mooney +1 more
2019Cancer Journal8 citations Open access
Semantic Scholar
Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
Julia Krushkal, Ying-Dong Zhao, Kyle Roney, Wei-Min Zhu +5 more
2024Epigenetics7 citations Open access
Semantic Scholar
Trastuzumab and Pertuzumab in Patients with non-Breast/Gastroesophageal HER2-amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol J
R. Connolly, V. Wang, David M. Hyman, P. Grivas +18 more
2024Clinical Cancer Research7 citations Open access
Semantic Scholar
Abstract 5671: Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project
Diana M. Merino, Laura M. Yee, L. McShane, P. Williams +33 more
2020Tumor Biology7 citations
Semantic Scholar
Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products
H. Sankaran, Simarjeet Negi, L. McShane, Ying-Dong Zhao +1 more
2022BMC Cancer6 citations Open access
Semantic Scholar
Phase 2 Study of Defactinib (VS6063) in Patients with Tumors with NF2 Loss: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol U
M. Zauderer, Opeyemi A. Jegede, D. M. Jackman, J. A. Zwiebel +18 more
2024JCO Precision Oncology5 citations Open access
Semantic Scholar
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.
D. Jackman, Opeyemi A. Jegede, M. Zauderer, E. Mitchell +14 more
20215 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Patton×20
Invite
D. Patton — researcher profile on SciRah
L. Harris×15
Invite
L. Harris — researcher profile on SciRah
P. Williams×13
Invite
P. Williams — researcher profile on SciRah
B. Conley×13
Invite
B. Conley — researcher profile on SciRah

×12

Invite

K. Flaherty — researcher profile on SciRah

Invite

R. Gray — researcher profile on SciRah

Invite

Shu-Li Li — researcher profile on SciRah

Alice P. Chen×10

Invite

Alice P. Chen — researcher profile on SciRah

S. Hamilton×10

Invite

S. Hamilton — researcher profile on SciRah

Invite

E. Mitchell — researcher profile on SciRah

L. Rubinstein×9

Invite

L. Rubinstein — researcher profile on SciRah

Invite

J. Tricoli — researcher profile on SciRah